Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Accumulated Expenses (2022 - 2024)

Historic Accumulated Expenses for Universe Pharmaceuticals (UPC) over the last 3 years, with Q3 2024 value amounting to $49.5 million.

  • Universe Pharmaceuticals' Accumulated Expenses rose 172447.7% to $49.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $49.5 million, marking a year-over-year increase of 172447.7%. This contributed to the annual value of $49.5 million for FY2024, which is 172447.7% up from last year.
  • As of Q3 2024, Universe Pharmaceuticals' Accumulated Expenses stood at $49.5 million, which was up 172447.7% from $2.7 million recorded in Q3 2023.
  • In the past 5 years, Universe Pharmaceuticals' Accumulated Expenses ranged from a high of $49.5 million in Q3 2024 and a low of $2.5 million during Q3 2022
  • Its 3-year average for Accumulated Expenses is $18.2 million, with a median of $2.7 million in 2023.
  • In the last 5 years, Universe Pharmaceuticals' Accumulated Expenses skyrocketed by 678.81% in 2023 and then soared by 172447.7% in 2024.
  • Universe Pharmaceuticals' Accumulated Expenses (Quarter) stood at $2.5 million in 2022, then rose by 6.79% to $2.7 million in 2023, then soared by 1724.48% to $49.5 million in 2024.
  • Its Accumulated Expenses was $49.5 million in Q3 2024, compared to $2.7 million in Q3 2023 and $2.5 million in Q3 2022.